Is there any long-term benefit in quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer?

Lee JH, Kim YW, Ryu KW (2007) A phase-II clinical trial of laparoscopy-assisted distal gastrectomy with D2 lymph node dissection for gastric cancer patients. Ann Surg Oncol. Aug 20; [Epub ahead of print] Shehzad K, Mohiuddin K, Nizami S et al (2007) Current status of minimal access surgery for gastric cancer. Surg Oncol 16(2):85–98. Epub 2007 Jun 7 Yasuda K, Shiraishi N, Etoh T, Shiromizu A, Inomata M, Kitano S (2007) Long-term quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer. Surg Endosc 21:2150–215 Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357(18):1810–1820 Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20 Roukos DH, Hottenrott C, Lorenz M, Koutsogiorgas Couchell S (1990) A critical-evaluation of effectivity of extended lymphadenectomy in patients with carcinoma of the stomach—an analysis of early results and long-term survival. J Cancer Res Clin 116(3):307–313 Siewert JR, Bottcher K, Stein HJ, Roder JD (1998) Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 228(4):449–461 Roukos DH, Kappas AM (2002) Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol 81(2):59–62 Kappas AM, Fatouros M, Roukos DH (2004) Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol 11(8):727–730 Roukos DH (2004) Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol Feb;11(2):127–129 Roukos DH, Hottenrott C, Encke A, Baltogiannis G, Casioumis D (1994) Primary gastric lymphomas: a clinicopathologic study with literature review. Surg Oncol 3(2):115–125 Gervasoni JE, Sbayi S, Cady B (2007) Role of lymphadenectomy in surgical treatment of solid tumors: an update on the clinical data. Ann Surg Oncol (in press) DOI: 10.1245/s10434-007-9360-5 Roukos DH, Kappas AM (2005) Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2:98–107 Roukos DH, Lorenz M, Karakostas K, Paraschou P, Batsis C, Kappas AM (2001) Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: a prospective with quality control 10-year follow-up study. Br J Cancer 84(12):1602–1609 Roukos DH (1998) Extended lymphadenectomy in gastric cancer: when, for whom and why. Ann R Coll Surg Engl 80(1):16–24 Roukos DH (2000) Extended (D2) lymph node dissection for gastric cancer: do patients benefit? Ann Surg Oncol 7(4):253–255 Roukos DH (1999) Current advances and changes in treatment strategy may improve survival and quality of life in patients with potentially curable gastric cancer. Ann Surg Oncol 6(1):46–56 Roukos DH, Lorenz M, Encke A (1998) Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. Surgery 123(5):573–578 Macdonald JS, Smalley SR, Benedetti J et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725–730 Roukos DH (2002) Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 9(3):220–221 Briasoulis E, Fatouros M, Roukos DH (2007) Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 14(10):2691–2695 Briasoulis E, Liakakos T, Dova L, Fatouros M, Tsekeris P, Roukos DH, Kappas AM (2006) Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 6(6):931–939 Norton JA, Ham CM, Van Dam J et al (2007) CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 245(6):873–879 Chung DC, Yoon SS, Lauwers GY, Patel D (2007) Case records of the Massachusetts General Hospital. Case 22–2007. A woman with a family history of gastric and breast cancer. N Engl J Med 357(3):283–291 Roukos DH, Murray S, Briasoulis E (2007) Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 6(3):308–312 Kim JJ, Song KY, Chin HM, Kim W, Jeon HM, Park CH, Park SM (2007) Totally laparoscopic gastrectomy with various types of intracorporeal anastomosis using laparoscopic linear staplers: preliminary experience. Surg Endosc Jun 26; [Epub ahead of print] Roukos DH, Briasoulis E (2007) Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 4:578–590 Roukos DH, Kappas AM, Tsianos E (2002) Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol 9(7):607–609 Roukos DH, Agnanti NJ, Paraskevaidis E, Kappas AM (2002) Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 9(10):941–943 Fatouros M, Baltoyiannis G, Roukos DH (2008) The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol 15:21–33 Agnantis NJ, Paraskevaidis E, Roukos D (2004) Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 11(12):1030–1034 Roukos DH (2007) Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357:1555–1556 Roukos DH, Kappas AM, Agnantis NJ (2003) Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 10(7):718–721 Fatouros M, Roukos DH, Arampatzis I, Sotiriadis A, Paraskevaidis E, Kappas AM (2005) Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 5(4):737–745 Roukos DH (2008) Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn 8(1):29–39 Liakakos T, Roukos DH (2008) More controversy than ever – challenges and promises towards personlized treatment of gastric cancer. Ann Surg Oncol 15(4):959–960 Roukos DH (2008) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 358:197 Roukos DH (2008) Linking contralateral breast cancer with genetics. Radiother Oncol 86:139–141